Detalhe da pesquisa
1.
Deep resolution of clinical, cellular, and transcriptomic inflammatory markers during 52 weeks of IL-17A inhibition by secukinumab.
Clin Exp Dermatol
; 2024 Jan 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38240024
2.
Investigation of plaque psoriasis relapse after secukinumab withdrawal in patients from two Phase 3 studies.
Clin Exp Dermatol
; 2023 Oct 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37820029
3.
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis.
J Am Acad Dermatol
; 83(3): 839-846, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32344071
4.
Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort.
J Am Acad Dermatol
; 89(2): 345-347, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36521798
5.
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial.
J Am Acad Dermatol
; 76(1): 70-80, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27707593
6.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
J Am Acad Dermatol
; 76(1): 60-69.e9, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663079
7.
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial.
J Am Acad Dermatol
; 73(3): 400-9, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26092291